X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Rhythm will acquire global rights for LB54640, an investigational oral small molecule MC4R agonist now in Phase 2 clinical trials for patients with acquired hypothalamic obesity and proopiomelanocortin, LEPR, or PCSK1 deficiency obesity.
Lead Product(s): LB54640
Therapeutic Area: Nutrition and Weight Loss Product Name: LB54640
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Rhythm Pharmaceuticals
Deal Size: $305.0 million Upfront Cash: $100.0 million
Deal Type: Licensing Agreement January 04, 2024
Details:
Under the terms of the agreement, LG Chem will supply UNICEF with its polio vaccine Eupolio and a pentavalent vaccine Eupenta that prevents diphtheria, pertussis, tetanus, hepatitis B and meningitis to solve global public health issues.
Lead Product(s): Sabin Inactivated Polio Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Eupolio
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: UNICEF
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Agreement March 14, 2023
Details:
LC350189 (tigulixostat) is a novel xanthine oxidase inhibitor targeting the reduction of uric acid in purine metabolism, by inhibiting the activity of xanthine oxidase.
Lead Product(s): Tigulixostat
Therapeutic Area: Rheumatology Product Name: LC350189
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Innovent Biologics
Deal Size: $95.5 million Upfront Cash: $10.0 million
Deal Type: Collaboration December 14, 2022
Details:
AVEO will establish LG Chem’s commercial presence in oncology through AVEO’s lead product, FOTIVDA® (tivozanib), which received U.S. FDA approval for the treatment of relapsed or refractory advanced renal cell carcinoma following two or more prior systemic therapies.
Lead Product(s): Tivozanib
Therapeutic Area: Oncology Product Name: Fotivda
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Aveo Oncology
Deal Size: $566.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition October 18, 2022
Details:
Results from US Phase 2 clinical trial—primary end point set at a challenging level confirmed the potential of LC350189 (tigulixostat) as a new gout treatment distinguished from pre-existing drugs, while also demonstrating safety similar to that of the placebo group.
Lead Product(s): Tigulixostat
Therapeutic Area: Rheumatology Product Name: LC350189
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2022
Details:
LG203003 is second NASH compound is formulated to suppress the accumulation of fat in liver cells by selectively impeding the activation of DGAT2 (diacylglycerol O-acyltransferase 2), a triglyceride synthetase, thus reducing liver cell damage.
Lead Product(s): LG203003
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: LG203003
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 14, 2022
Details:
LG Chem is strengthening its anti-cancer sector through advanced construction of cell drug platform technologies. LR19023, the next-generation CAR-T cell treatment, is currently in the pre-clinical stage and under development as a solid cancer therapeutic.
Lead Product(s): LR19023
Therapeutic Area: Oncology Product Name: LR19023
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: MaxCyte
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 12, 2022
Details:
Under the terms of the agreement, LG Chem has the exclusive rights to develop and commercialise, on a global basis, Avacta’s Affimer® PD-L1 inhibitor (PD-L1 XT) with Affimer XT™ serum half-life extension for a range of indications.
Lead Product(s): PD-L1 XT
Therapeutic Area: Oncology Product Name: PD-L1 XT
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Avacta Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Expanded Collaboration June 30, 2022
Details:
The partnership provides LG Chem with rights to develop and commercialise other Affimer® and non-Affimer biotherapeutics combined with Affimer XT® half-life extension for a range of indications.
Lead Product(s): PD-L1 XT
Therapeutic Area: Oncology Product Name: PD-L1 XT
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Avacta Group
Deal Size: $453.5 million Upfront Cash: Undisclosed
Deal Type: Partnership September 29, 2021
Details:
Under the terms of the agreement, LG Chem will obtain exclusive worldwide rights, except Greater China region and Japan, to develop and commercialize TT-01025.
Lead Product(s): TT-01025
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: TT-01025
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: TransThera Biosciences
Deal Size: $350.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 18, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
